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Summary. The cellular metabolism of 3'-amino-2',3'- 
dideoxycytidine (3'-NHz-dCyd), a cytotoxic agent pre- 
viously reported to be a poor substrate for purified 
Cyd/dCyd deaminase (dCydD), was compared with that of 
cytosine arabinoside (ara-C) in cells that displayed dCydD 
activity (HeLa) and in cells that did not (L1210). Growth 
inhibition induced by 3'-NH2-dCyd was dependent on the 
levels of anabolic enzymes, particularly dCyd kinase 
(dCydK), whereas cytotoxicity induced by ara-C was de- 
pendent on the expression of both anabolic and catabolic 
enzyme activities. Competition kinetics using purified 
enzyme revealed that the binding affinity of axa-C to 
dCydK was 5-fold that of the amino analog. However, this 
binding advantage is apparently offset in cells that contain 
high levels of dCydD, since the Ki values for this enzyme 
were 0.2 and 23 mM for ara-C and 3'-NHz-dCyd, respec- 
tively. This was reflected in the decrease in analog sensi- 
tivity observed between the two cell lines, whereby the 
concentrations of ara-C and 3'-NH2-dCyd required to in- 
hibit growth by 50% were 200 and 7 times higher, respec- 
tively, in the dCydD-containing HeLa cells as compared 
with the dCydD-deficient L1210 cells. The metabolic sta- 
bility and cytotoxicity of 3'-NH2-dCyd was independent of 
cell number. An unexpected finding was the extent to 
which the effectiveness of ara-C could be mitigated by the 
number of dCydD-containing cells. A completely cytotox- 
ic concentration of ara-C was rendered nontoxic by a 
10-fold increase in cell number. This observation was 
supported by an increase in I-[~-D-arabinofuranosyluracil 
(ara-U) formation, a decrease in ara-C 5'-triphosphate 
(ara-CTP) accumulation, and a rise in cell viability with 
increasing cell number. These findings indicate that unlike 
* Supported by grant CH-452 from the American Cancer Society 
Offprint requests to: W, R. Mancini, Department of Pharmacology 
M6322 Medical Science Bldg. 1, University of Michigan Medical 
School, Ann Arbor, M148109-0626, USA 
ara-C, the effectiveness of 3'-NH2-dCyd is independent of 
the level of deaminase, which suggests its possible utility 
in situations in which high levels of deaminase are 
manifest. 
Introduction 
3'-Amino-2',3'-dideoxycytidine (3"-NH2-dCyd) is a cyto- 
toxic agent that has been demonstrated to be active against 
murine leukemia in vitro and in vivo [16]. A unique feature 
of this analog is that it serves as a nominal substrate for 
human cytidine/deoxycytidine deaminase (dCydD), the 
enzyme that is responsible for the short biological half-life 
of cytosine arabinoside ara-C I-[~-D-arabinofuranosylcy- 
tosine [2, 7, 11] by converting it to noncytotoxic I-~-D-ara- 
binofuranosyluracil (ara-U) [4, 5, 11]. It is known that the 
plasma half-life of ara-C varies among patients [2, 7, 8, 26] 
and in some cases of acute myeloblastic leukemia (AML); 
especially when ara-C is given as a single agent, refractor- 
iness to treatment with this drug has been shown to corre- 
late with a short half-life of ara-C [2] and with elevated 
levels of deaminase activity in leukemic blasts [25]. Such 
findings prompted an investigation to explore the possibil- 
ity of developing a cytotoxic, deaminase-resistant dCyd 
analog for the treatment of acute leukemia. 
Although the antileukemic effect of 3'-NHz-dCyd is 
believed to result from an inhibition of DNA replication 
[16, 19], little is known about the metabolism that occurs in 
intact cells. Furthermore, in addition to dCydD, cells also 
contain deoxycytidylate deaminase (dCMPD). If the amino 
analog is a good substrate for this degradative enzyme, it 
would be inactivated because the corresponding deoxy- 
uridine (dUrd) derivative is significantly less cytotoxic 
[16, 19]. The aim of the present investigation was to eval- 
uate the cytotoxic effect of 3'-NH2-dCyd in cells display- 
ing dCydD activity and in those exhibiting no such activi- 
ty. Since ara-C is a good substrate for this enzyme, it was 
studied for comparison. 
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Table 1. Cell-line comparison of analog sensitivity and the levels of dCyd-metabolizing enzymes 
ICs0 (gM) a Enzyme activity (unit/mg) b 
Cells Ara-C 3'-NH2-dCyd dCydK dCMPK dCydD dCMPD 
L1210 0.02 0.6 0.108+ 0.004 5.37 +_ 0.33 0 c 2.43 _+0.17 
HeLa 4.4 3.9 0.051 _+ 0.005 8.87 + 0.76 5.90 _+ 0.66 5.57 + 0.37 
a ICs0 values were calculated from 72-h dose-response curves [22]. The 
starting cell density was 1 x 104 and 1 x 105 cells/ml medium for L1210 
and HeLa cells, respectively 
b The conditions for cell growth were the same as those used to deter- 
mine dose response except that no drug was present. Enzyme activities 
were determined in duplicate immediately after culture harvest for each 
experiment. Data represent mean values _+ SEM (dCydK and dCydD, 
n = 3 experiments; dCMPK and dCMPD, n = 2 determinations). One 
unit is the amount of enzyme which catalyzes the formation of 1 nmol 
product from substrate per min at 32~ 
c No enzyme activity detected 
Materials  and methods  
Chemicals. 3'-NH2-dCyd was kindly provided by Dr. T.-S. Lin of Yale 
University. Unlabeled nucleosides and nucleotides were purchased from 
Sigma Chemical Co. (St. Louis, Mo.). [2-14C]-dCyd, [2-14C]-dCMP 
(56 mCi/mmol) and [5,6-3H]-ara-C (26 Ci/mmol) were obtained from 
Moravek Biochemicals (Brea, Calif.). [6-3H]-3-NH>dCyd 
(0.75 Ci/mmol) was prepared using the tritium labeling service of New 
England Nuclear (Boston, Mass.) and subsequently purified as described 
elsewhere [20]. All other chemicals were reagent grade. 
Cells. L1210 cells were obtained from the NCI-Frederick Cancer Re- 
search Facility, and HeLa and KB cells were purchased from the Ameri- 
can Type Culture Collection. L1210 cells were grown in Fischer's me- 
dium (Gibco, Grand Island, N.Y.) supplemented with 10% horse serum, 
whereas HeLa cells were propagated in RPMI 1640 supplemented with 
10% fetal bovine serum (Gibco). For growth-inhibition studies, cells in 
logarithmic growth were incubated for 72 h with various concentrations 
of either ara-C or 3'-NH2-dCyd. Cultures were harvested and the cell 
number was determined using a model ZM Coulter counter (Hialeah, 
Fla.). 
Enzyme levels. For determination of the dCyd-metabolizing enzyme 
levels, cultures were propagated under the same conditions used for the 
growth-inhibition studies, except that no drug was present during the 
incubation. All harvest procedures were performed at 5 ~ C. After 72 h 
growth, cultures were collected by low-speed centrifugation and washed 
twice with phosphate-buffered saline. Extraction buffer [25 mM HEPES 
(pH 7.5), 3 mu MgC12 and 4 mM dithiothreitol (DTT)] was added to the 
pellet prior to three freeze-thaw procedures. Following the addition of 
KC1 (final concentration, 0.15 M), the samples were sonicated with three 
5-s blasts. Glycerol was added to 10% of the volume before centrifuga- 
tion of the samples in an Eppendorf microcentrifuge. The supernatant 
was immediately used for determination of enzyme levels. 
dCMPD was assayed as reported elsewhere [18]. The dCydD assay 
was carried out essentially as described for dCMPD, except that 1 mM 
dCyd was used instead of dCMP and the dCTP was omitted from the 
reaction mixture. The dCyd kinase (dCydK) assay was performed essen- 
tially as previously described [17], except that 0.35 trim tetrahydrouridine 
and 25 mM NaF were included in the reaction mixture for assay of the cell 
homogenate. The analysis of deoxycytidylate kinase (dCMPK) was car- 
ried out as previously described [6]. However, the contents of the assay 
mixture were modified so as to obtain maximal enzyme activity. The 
reaction mixture contained 50 mM HEPES (pH 7.5), 5.6 mM phos- 
phocreatine, 0.5 unit (Sigma Chemical Co.) phosphocreatine kinase, 
7 unit (Sigma Chemical Co.) nucleoside diphosphate kinase, 75 ~tg 
bovine serum albumin, 2 rrcu DTT, 2 mM adenosine 5'-triphosphate 
(ATP), 1 rnM thymidine 5'-monophosphate (TMP; all obtained from 
Sigma Chemical Co., St. Louis, Mo.), 2 mM [2-14C]-dCMP 
(0.37 mCi/mmol), and 2 mM MgC12. 
Enzyme purification. The purification of dCydK from L1210 cells has 
been reported [ 17]. Since L 1210 cells do not exhibit dCydD activity, this 
enzyme was isolated from human KB cells. The procedure for the extrac- 
tion and purification of dCydD up to the thymidine-affinity column step 
was performed as described elsewhere [19]. For the removal of residual 
dCydK activity, the preparation was applied to a Blue Sepharose CL-6B 
(Pharmacia, Piscataway, N.J.) column and eluted with buffer [0.2 M 
TRIS-HC1 (pH 7.5), 2 mM DTT, and 10% glycerol]. Fractions containing 
dCydD activity were pooled and the sample was applied to a DE-52 
(Whatman, Hillsboro, Ore.) anion-exchange column. The enzyme eluted 
in a gradient [containing 0.05 M TRtS-HC1 (pH 7.5), 2 mM DTT, and 
10% glycerol] of increasing ionic strength (0-0.5 M KC1). The purified 
enzyme was desalted using a G-25 Sephadex (Sigma Chemical Co., St. 
Louis, Mo.) column before its use in the kinetics experiments. 
Cellular metabolism of analogs. To assess the degree of metabolic deg- 
radation by cellular dCydD, HeLa cells were incubated with radiolabeled 
analogs at the concentrations required to inhibit growth by 50% (IC50). 
Either 4 gM [5,6-3H]-ara-C or [6-3H]-3'-NHa-dCyd was incubated with 
the indicated number of cells for 26 h. Cells were removed by centrifuga- 
tion and the medium was extracted in 60% methanol. An aliquot of the 
supernatant was applied to silica thin-layer chromatography (TLC) 
plates, which were developed in n-butanol, glacial acetic acid, and water 
(2:1 : 1, by vol.). Areas migrating with standard compounds were re- 
moved, and radioactivity was quantitated by liquid scintillation spec- 
trometry. Each determination was carried out in triplicate for each exper- 
inaent. 
Determination ofara-CTP levels. For the separation of ribonucleotides 
from the desired deoxyribonucleotides contained within the methanol 
extracts, boronate affinity chromatography (Bio-Rad) was used. The 
eluate containing nucleosides and nucleotides that lacked 2',3'-hydroxyls 
in the cis configuration was analyzed by HPLC using the anion-exchange 
matrix [10]. [3H]-Ara-C 5'-triphosphate ([3H]-ara-CTP) which eluted in 




T h e  abi l i ty  o f  3 ' - N H 2 - d C y d  and ara-C to inh ib i t  the  rep-  
l i ca t ion  o f  L 1 2 1 0  (wi thou t  d C y d D )  and H e L a  (wi th  
d C y d D )  cel ls  f o l l o w i n g  a 72-h  i ncuba t i on  was  eva lua ted .  
L o g i t  t r ans fo rma t ion  [22] o f  the d o s e - r e s p o n s e  cu rves  es-  
t ab l i shed  the  IC50 va lue ,  w h i c h  was  found  to v a r y  about  7-  
and 2 0 0 - f o l d  b e t w e e n  the ce l l  l ines  fo r  3 ' - N H 2 - d C y d  and 
ara-C,  r e s p e c t i v e l y  (Tab le  1). S ince  bo th  agents  are  
S -phase - spec i f i c ,  i t  s e e m e d  r ea sonab l e  that  d i f f e rences  in 
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Fig. I A - D .  Effect of cell number on analog sensitivity. A, C L1210 in the same volume of medium and were incubated for 48 h in the 
cells that failed to display nucleoside deaminase activity and B, D HeLa presence of varying concentrations of A, B ara-C or C, D 3'-NHz-dCyd. 
cells that exhibited such activity were seeded at the indicated cell density Each result represents the average value + SEM for 3 separate cultures 
Activities of dCyd-metabolizing enzymes 
Table 1 depicts the levels o f  dCyd-metabol iz ing enzymes 
found for each cell line. L1210 cells exhibited about twice 
the d C y d K  activity shown for HeLa cells. In addition, the 
doubling times were 11 h for L1210 vs 25 h for HeLa. 
These two factors could have accounted for much of  the 
variation in ICs0 values for 3 ' -NH2-dCyd observed be- 
Table 2. Analog Ki values for dCydK and dCy,tD 
Ki (mM) a 
Enzyme Ara-C 3'-NH2-dCyd 
dCydK 0.3 1.5 
dCydD 0.2 23.4 
The dCydK and dCydD reactions were canied out using fixed dCyd 
concentrations and varying concentrations of inhibitor (ara-C or 3'-NH2- 
dCyd). Lineweaver-Burk plots were linear and showed competitive inhi- 
bition. Linear regression analysis was used both to calculate the 
Lineweaver-Burk slopes and to determine the Ki value from the replot 
(slope vs inhibitor concentration). The correlation coefficients of the 
replots for ara-C and 3'-NH2-dCyd, respectively, were 0.9987 and 0.9984 
for dCydK (n = 7) and 0.9991 and 0.9965 for dCydD (n = 5) 
tween the cells. However,  with respect to ara-C, an addi- 
tional parameter is required to account  for the wide varia- 
tion in drug sensitivity. The presence of  high deaminase 
levels in HeLa cells may  have contributed to the difference 
between these drugs, since ara-C is known to be a good 
substrate for dCydD. 
KI determination 
The data suggest that the levels o f  dCyd enzymes may have 
influenced the observed variation in cytotoxicity. The Ki 
value for the analogs was determined for the first enzyme 
involved in both the activation and the degradation path- 
ways. The respective Ki values for ara-C and 3 ' -NH2-dCyd 
were 0.3 and 1.5 mM for dCydK and 0.2 and 23.4 mM for 
dCydD (Table 2). 
Influence of cell number on analog sensitivity 
I f  the presence o f  deaminase is a major  factor in drug-sen- 
sitivity variations between cells, then the magnitude of  the 
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Fig. 2. Effect of cell number on ara-CTP levels. HeLa cells were grown 
in the presence of 1.2 gs~ [3H]-ara-C at varying (1-, 2-, and 5-fold) cell 
densities in the same volume of medium. At the indicated times, cultures 
were harvested and the amount of ara-CTP (pmol/107 cells) was deter- 
mined by HPLC. The data obtained at 1- and 5-fold cell densities repre- 
sent average values _+ SEM for 2 separate experiments 
Table 3. Effect of cell number on the extent of ara-C or 3'-NH2-dCyd 
deamination in HeLa cells 
Cell number a [3H]-AraU b [3H]-3'-NH2-dUrdb 
(% total cpm) (% total cpm) 
5• 104 61.2_+3.12 
1 • 105 82.2+2.57 0.748_+0.61 c 
2 x 105 91.4_+0.93 
5 x 105 95.6+0.14 0.540_+0.58 ~ 
a Cell number at the time of addition of radiolabeled drug (4 gM) to the 
medium. Each determination was carried out in triplicate for each exper- 
iment. Incubations lasted 26 h 
b Data represent average values __ SE for 2 separate experiments ex- 
cept for those obtained for ara-C at 1 x 105 and 5 • 105 cells (n = 3 
experiments). Compounds were resolved using TLC [silica supple- 
mented with n-butanol, acetic acid, and water (2 : 1 : 1, by vol.)] and the 
amount of radioactivity was quantitated by scintillation spectrometry. 
The total counts per minute measured for the drug and its deaminated 
derivative were approx. 6,000 and 4,000 for ara-C and 3'-NH2-dCyd, 
respectively 
c Level of 3'-NH2-dUrd formed was not significant according to Stu- 
dent's two-tailed t-test (P <0.001) 
increase in cell number rendered this concentration 
completely nontoxic (Fig. 1 B). To rule out the possibility 
that only growth delay was altered by the change in cell 
number, cell viability was examined using a clonogenic 
assay. At 5 and 7.5 ~M ara-C, the extent of colony forma- 
tion as compared with that in untreated cells was 
13% + 3% and 5.7% -+ 3%, respectively, at the lowest cell 
number and 76% + 7 %  and 79%_+7%, respectively, at a 
5-fold higher cell number. 
Analog deamination in intact cells 
The data suggest that dCydD may play a significant role in 
reducing the cytotoxic effectiveness of  ara-C but not 
3'-NH2-dCyd. Thus far, observations implicating deami- 
nase that have been drawn from experiments using isolated 
enzymes and intact cells have been indirect. To provide 
more direct documentation of deaminase involvement in 
this process, the formation of drug metabolites in cultured 
cells was examined. HeLa cells were grown in the presence 
of radiolabeled ara-C or 3'-NH2-dCyd at their ICs0 concen- 
trations. After 26 h, the medium was removed and the 
degree of analog deamination was quantitated (Table 3). 
No significant amount of 3'-amino-2',3'-dideoxyuridine 
(3'-NH2-dUrd) was detected, even at the highest cell num- 
ber used (Table 3). This finding is consistent with the 
previous observation and suggests that 3'-NH2-dCyd is 
metabolically more stable than ara-C in intact cells that 
express dCydD. 
In ara-C-treated cells, the amount of  radiolabeled ara-U 
formed correlated with the starting cell number. At the 
highest cell number, >95% of the total radioactivity was 
present as the deaminated derivative. This cell-number-de- 
pendent degradation of ara-C should be reflected in the 
level of  ara-CTP, since the amount of this metabolite has 
been shown to be a determinant in predicting the response 
to therapy [24]. Figure 2 reveals that the formation of 
ara-CTP decreased with increasing numbers of  cells. 
D i s c u s s i o n  
effect may be influenced by the amount of  enzyme activity 
that is expressed at the time at which the drug is added to 
the medium. One way to test this hypothesis is to expose 
increasing numbers of cells to a fixed concentration of 
analog as demonstrated in Fig. 1. 
In L1210 cells, which display no detectable dCydD 
activity, cell number did not influence the cytotoxic effect 
of either agent (Fig. 1 A, C). Similarly, in the dCydD-con- 
taining HeLa cells, the level of  cytotoxicity induced by 
3'-NH2-dCyd was not mitigated by a 10-fold increase in 
cell number (Fig. 1 D). This implies that the amino analog 
is metabolically stable even in cells that contain high levels 
of deaminase. In contrast, the influence of the number of 
HeLa cells on ara-C-induced toxicity was substantial. For 
example, an ara-C concentration of 0.8 [AM completely pre- 
vented cell replication at the low cell number, but a 10-fold 
Ara-C is an important part of  our armamentarium in the 
treatment of acute leukemia in children and adults [3, 9, 
12]. A major limitation recognized by many investigators 
is the short biological half-life of  this agent caused pri- 
marily by the action of dCydD, which degrades ara-C to 
noncytotoxic ara-U [4, 5, 11]. Potential ways to circumvent 
this problem include the use of high-dose ara-C therapy 
[1, 15, 21, 23] in an attempt to saturate the deaminase and 
the coadministration of tetrahydrouridine with ara-C to 
inhibit dCydD [13, 14, 27]. However, in either method, the 
optimization of clinical therapy may be hindered due to 
variations in the dCydD levels in the liver, plasma, and 
tumor. An alternative approach to circumvent the enzymic 
inactivation of ara-C involves the use of a dCyd derivative 
that is not a substrate for dCydD but serves as a substrate 
for the kinases that are essential to the formation of the 
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active metabolite (triphosphate derivative). Such an agent 
may be useful because it would enable the clinician to 
initiate therapy without regard to the interpatient variabili- 
ty of deaminase activity. 
3'-NHz-dCyd has been observed to be cytotoxic to cul- 
tured murine L 1210 and S- 180 cells at an IC50 value of 0.7 
and 4 gM, respectively [16]. This dCyd derivative has also 
shown activity in mice bearing L1210 leukemia [16], and 
four of five mice survived for 60 days after the treatment 
schedule had been optimized [20]. The compound is con- 
verted by cellular enzymes to the triphosphate, which 
specifically inhibits DNA synthesis [20] but not RNA or 
protein synthesis [16]. 3'-NHz-dCyd has been found to be 
resistant to deamination using an in vitro assay for dCydD 
[19]. However, the finding that L1210 cells are devoid of 
dCydD and that the deaminated derivative 3'-NH2-dUrd is 
not active in vitro [19] or in vivo [16] prompted an evalua- 
tion using deaminase-containing cells. The data obtained 
in the present investigation using intact cells that contained 
high levels of both nucleoside and nucleotide deaminase 
suggest that the biological activity of 3'-NHz-dCyd is not 
mitigated by the presence of these enzymes (Table 1). 
Although both analogs showed variations in cytotoxic- 
ity to the cell types tested, the magnitude of this effect was 
greater for ara-C (200-fold) than for 3'-NHz-dCyd (7-fold). 
The parameters that appear to correlate with this observa- 
tion are the levels of activity of dCyd-metabolizing 
enzymes. In the murine cells that contained no dCydD and 
only low levels of dCMPD, the IC50 value for ara-C was 30 
times lower than that for the amino analog (Table 1). This 
may have been due in part to the 5-fold lower binding 
affinity of ara-C for dCydK. There was little difference in 
the level of dCMPK between these cell types, but the 
presence of a 2-fold higher dCydK level coupled with a 
faster doubling time could have accounted for the greater 
sensitivity of L1210 cells to both agenl:s. 
An unexpected finding in the present study was that the 
effectiveness of ara-C but not of 3'-NH2-dCyd was depen- 
dent on the number of dCydD-containing cells. In HeLa 
cells, the presence of high dCydD levels suggests that the 
5-fold binding advantage of ara-C for dCydK is apparently 
offset by the 117-fold lower binding affinity of 3'-NH2- 
dCyd for dCydD (Table 2). The result is that the cytotoxic 
effectiveness of ara-C is greatly reduced, whereas that of 
3'-NHz-dCyd is not affected by these levels of dCydD. 
This is exemplified in Fig. 1. In cells that did not exhibit 
dCydD activity (L1210), cell number had no effect on the 
cytotoxicity of either agent (Fig. 1 A, C). In the deaminase- 
containing HeLa cells, the ICs0 value for 3'-NH2-dCyd was 
about 4 gM and was independent of cell number (Fig. 1 D); 
under the same conditions, the IC50 value for ara-C varied 
significantly and cytotoxicity was dependent on cell num- 
ber (Fig. 1B). At low concentrations of ara-C, a 10-fold 
increase in cell number greatly diminished the observed 
cytotoxicity (Fig. 1 B). Consistent with this finding was the 
correlation of the extent of ara-C degradation with increas- 
ing cell number (Table 3) as well as with a reduction in the 
level of ara-CTP. 
The clinical implications of these findings are that the 
total number of cells that express dCydD, both normal 
(i. e., liver) and neoplastic (tumor burden), may play a role 
in the interpatient variability and the overall response to 
ara-C therapy. Therefore, under conditions in which high 
activity of dCydD is manifest, a deaminase-resistant ana- 
log such as 3'-NH2-dCyd may be of potential value, since 
the effectiveness of this compound would be independent 
of tissue deaminase levels. 
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